A randomized, placebo-controlled trial of an antisense ICAM-1 inhibitor (ISIS 2302) in steroid-dependent Crohn's disease showed clinical improvement at high serum levels

✍ Scribed by Yacyshyn, Bruce R.; Chey, W.Y.; Goff, J; Salzberg, B; Baerg, R; Buchman, A.L.; Tami, Joseph A.; Shanahan, William R.

• Book ID: 124135059
• Publisher: Elsevier Science
• Year: 2001
• Tongue: English
• Weight: 341 KB
• Volume: 120
• Category: Article
• ISSN: 0016-5085
• DOI: 10.1016/S0016-5085(08)81386-8